Skip to content
pppppppp

Our story

This website was established to offer an accessible source of information featuring the most recent updates on the application of intravesical sequential doublet chemotherapy, which encompasses gemcitabine/docetaxel (Gem/Doce), Gem/mitomycin C (Gem/MMC), and valrubicin/Doce (Val/Doce) for treating non-muscle-invasive bladder cancer (NMIBC).

Intravesical Gemcitabine/Docetaxel therapy

What constitutes Gem/Doce therapy?

Intravesical gemcitabine and docetaxel therapy treats non-muscle invasive bladder cancer by directly delivering chemotherapy into the bladder, targeting cancer cells while reducing systemic side effects.

 

Download the Gem/Doce Info sheet

 

 

Upcoming research

 

 

Tips and tricks for better tolerability of intravesical Gemcitabine/Docetaxel therapy

These strategies can help make the treatment more tolerable and improve patient comfort. They are based on the treatment experiences of over 500 patients and multiple regimen adjustments to optimize outcomes.

Download the tips and tricks file here

 

 

General information on intravesical Valrubicin/Docetaxel therapy 

What constitutes Valrubicin/Docetaxel therapy?

 

Intravesical Valrubicin/Docetaxel therapy consists of the sequential administration of valrubicin and docetaxel for treating high-risk non-muscle invasive bladder cancer, especially in patients who do not respond to BCG or gemcitabine/docetaxel therapies.

 

Access the information sheet on intravesical valrubicin/docetaxel

Recent findings released by our team on intravesical chemotherapy for NMIBC

 

1-Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer

2-Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?

3-Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor

4-Intravesical sequential gemcitabine/docetaxel for non-muscle invasive bladder cancer: tips and tricks for better efficacy and tolerability

5-Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer

6-Establishing an Intravesical Doublet Chemotherapy Clinic for Nonmuscle-Invasive Bladder Cancer Patients

7-Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer

8-Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naïve non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel

9-Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Guérin for the treatment of upper tract carcinoma in situ

10-Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.

11-Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer

13-Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma

 

Recent data published by other groups on intravesical chemotherapy for NMIBC

1-A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder

2-Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer

3-Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC .

4-Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer

5-Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols

6-Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC

7-Sequential Intravesical Chemotherapy for Treatment Naïve, High-Risk Non-Muscle Invasive Bladder Cancer: Oncologic Outcomes, Tolerance, and Comparison to Contemporary Controls

8-Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis

9-Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis

10-Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study

11-Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer

12-An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer

13-Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro

14-Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection

15-A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer

16-Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results

 

 

Strategies to optimize outcomes for patients with non-muscle invasive bladder cancer
Establishing an intravesical chemotherapy clinic

Establishing an intravesical chemotherapy clinic significantly enhances patient care by providing specialized, targeted treatments for non-muscle-invasive bladder cancer, leading to better outcomes and improved quality of life.

 

Complete Transurethral Resection of Bladder Tumor

Complete TURBT is crucial for patients with non-muscle-invasive bladder cancer because it ensures accurate tumor staging and grading, reduces the risk of recurrence, and optimizes patient outcomes

Adhering to Guidelines in Managing Non-Muscle-Invasive Bladder Cancer

Following guidelines is essential for ensuring the best possible outcomes for patients with non-muscle-invasive bladder cancer. Adhering to established protocols helps in accurate diagnosis, effective treatment, and reducing the risk of recurrence. It also ensures that patients receive standardized, high-quality care tailored to their specific needs.

Collaborative Research and Clinical Trials

Collaborative research and clinical trials advance medical science and improve patient outcomes by combining expertise and accelerating treatment development

Patient Education

Engage patients in shared decision-making to empower them in managing their cancer effectively